Aclaris Therapeutics Gets Fast-Track Designation for Inflammation Treatment Modzatinib

Dow Jones08-07 05:34

Aclaris Therapeutics said its modzatinib as a treatment for lichen planus received fast-track designation from the Food and Drug Administration.

Lichen planus is an autoimmune disorder that can cause rash on the skin and inside the mouth. The drug is designed as a treatment for moderate to severe lichen planus, including oral erosive LP, cutaneous LP, and lichen planopilaris, the company said. Aclaris added it expects to initiate a phased multi-part Phase 2b trial of the treatment in the fourth quarter.

The fast-track designation is given to expedite the review of new drugs that target serious conditions and fill an unmet need, according to the FDA.

The company's shares closed the day's regular trading session with a 4.25% loss, at $6.09. After the bell, following news of the fast-track designation, shares spiked to around $6.47 before giving up ground and returning to flat about an hour into the late trading session.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2657558666?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 05:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657558666","market":"us","top_or_hot":-1,"title":"Aclaris Therapeutics Gets Fast-Track Designation for Inflammation Treatment Modzatinib","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ACRS\">Aclaris Therapeutics</a> said its modzatinib as a treatment for lichen planus received fast-track designation from the Food and Drug Administration. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/LICN\">Lichen</a> planus is an autoimmune disorder that can cause rash on the skin and inside the mouth. The drug is designed as a treatment for moderate to severe lichen planus, including oral erosive LP, cutaneous LP, and lichen planopilaris, the company said. Aclaris added it expects to initiate a phased multi-part Phase 2b trial of the treatment in the fourth quarter. \n</p>\n<p>\n  The fast-track designation is given to expedite the review of new drugs that target serious conditions and fill an unmet need, according to the FDA. \n</p>\n<p>\n  The company's shares closed the day's regular trading session with a 4.25% loss, at $6.09. After the bell, following news of the fast-track designation, shares spiked to around $6.47 before giving up ground and returning to flat about an hour into the late trading session. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aclaris Therapeutics Gets Fast-Track Designation for Inflammation Treatment Modzatinib</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAclaris Therapeutics Gets Fast-Track Designation for Inflammation Treatment Modzatinib\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-08-07 05:34</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ACRS\">Aclaris Therapeutics</a> said its modzatinib as a treatment for lichen planus received fast-track designation from the Food and Drug Administration. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/LICN\">Lichen</a> planus is an autoimmune disorder that can cause rash on the skin and inside the mouth. The drug is designed as a treatment for moderate to severe lichen planus, including oral erosive LP, cutaneous LP, and lichen planopilaris, the company said. Aclaris added it expects to initiate a phased multi-part Phase 2b trial of the treatment in the fourth quarter. \n</p>\n<p>\n  The fast-track designation is given to expedite the review of new drugs that target serious conditions and fill an unmet need, according to the FDA. \n</p>\n<p>\n  The company's shares closed the day's regular trading session with a 4.25% loss, at $6.09. After the bell, following news of the fast-track designation, shares spiked to around $6.47 before giving up ground and returning to flat about an hour into the late trading session. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACRS","symbol_name":"Aclaris Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2657558666","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657558666","pubTimestamp":1786052040,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Aclaris Therapeutics said its modzatinib as a treatment for lichen planus received fast-track designation from the Food and Drug Administration.Lichen planus is an autoimmune disorder that can cause r","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACRS":"Aclaris Therapeutics","BK4007":"制药"},"translate_title":"Aclaris Therapeutics 获得炎症治疗 Modzatinib 快速通道认证","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACRS":1.5},"content_text":"Aclaris Therapeutics said its modzatinib as a treatment for lichen planus received fast-track designation from the Food and Drug Administration. \n\n\nLichen planus is an autoimmune disorder that can cause rash on the skin and inside the mouth. The drug is designed as a treatment for moderate to severe lichen planus, including oral erosive LP, cutaneous LP, and lichen planopilaris, the company said. Aclaris added it expects to initiate a phased multi-part Phase 2b trial of the treatment in the fourth quarter. \n\n\n  The fast-track designation is given to expedite the review of new drugs that target serious conditions and fill an unmet need, according to the FDA. \n\n\n  The company's shares closed the day's regular trading session with a 4.25% loss, at $6.09. After the bell, following news of the fast-track designation, shares spiked to around $6.47 before giving up ground and returning to flat about an hour into the late trading session.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2657558666","isCrawlerRequest":true}